Vail, Colorado – 03-12-2019 (PRDistribution.com) — The Greyledge Platform adds to the IWEUS HEALTH laboratory business growth strategy in bone marrow and blood-derived cellular therapeutic products.  

Focused on advancing the next frontier of orthobiologics, IWEUS HEALTH today announced they have entered into a definitive agreement to acquire majority interest of Greyledge Technologies, LLC. IWEUS HEALTH is a privately held investment management company focused in the acquisition of cGXP laboratories and the development of healthcare capital projects. Greyledge is an FDA registered cellular therapy platform currently used in Orthopaedic and Cosmetic applications. This acquisition will accelerate the IWEUS HEALTH entry into translational healthcare with the potential for growth and expansion into other applications. Additionally, it allows IWEUS HEALTH the opportunity to provide physicians with a means to quantify orthobiologics for accurate clinical decisions and a means to document the product for patient records.    

“Ultimately, we are positioned to improve quality standards and higher level data collection for cellular therapies in this surging area of healthcare. We provide a technology platform that allows physicians the opportunity to integrate quantitative analytics, data collection platforms, drive efficiencies, and offer autologous biological preparations, which are customizable to patients’ need and clinical application” said Dr David Karli, CEO and founder of Greyledge.  

With this acquisition, David Karli, MD, MBA, will join the ownership group with James Clarke, CEO, IWEUS HEALTH, upon the completion of this transaction.

“We are excited to be joining together, to establish a framework, a set of standards and assessment guidelines for physicians and scientists producing autologous biologics. We integrate a fully documented quality management system that we can scale and replicate across the country. Together, we will enable physicians, within their practice of medicine, to generate better patient outcomes with cellular therapies” said James Clarke.


IWEUS HEALTH an investment management firm specializing in acquisitions and the development of healthcare capital projects. We develop regenerative surgical healthcare facilities, and acquire mid-market Current Good Manufacturing, Laboratory, and Tissue Practice (cGXP) laboratories that specialize in bio-analysis, cellular therapy, and tissue engineering. We build our portfolio through acquisition, with operational excellence and a disciplined investment strategy.  

For more information, visit www.iweushealth.com


James Clarke, CEO, IWEUS HEALTH  

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sales of securities in any jurisdiction in which such offer, solicitation or sales would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.  This press release may contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding the acquisition of Greyledge Technologies. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of IWEUS HEALTH.


Media Contacts:

Company Name: IWEUS HEALTH
Full Name: James Clarke
Email Address: Send Email
Website: www.iweushealth.com

For the original news story, please visit https://prdistribution.com/news/iweus-health-announces-agreement-to-acquire-greyledge-technologies.html.